DEPRECIATION, SHARE-BASED PAYMENTS, EMPLOYEE AND OTHER EXPENSES

12 Months Ended

Dec. 31, 2021

DEPRECIATION, SHARE-BASED PAYMENTS, EMPLOYEE AND OTHER EXPENSES

DEPRECIATION, SHARE-BASED PAYMENTS, EMPLOYEE AND OTHER EXPENSES

21.    DEPRECIATION, SHARE-BASED PAYMENTS, EMPLOYEE AND OTHER EXPENSES

	For the years ended December 31,
	2021		2020		2019
EXPENSES
Selling expenses
Share-based payment	$	685,273	$	320,886	$	188,930
Cash-based employee expenses		921,772		891,784		526,769
Other expenses		1,389,247		984,133		930,286
	$	2,996,292	$	2,196,803	$	1,645,985
General and administrative expenses
Depreciation		307,015		280,949		182,202
Share-based payments		3,801,729		2,820,369		1,748,660
Cash-based employee expenses		3,218,867		3,149,313		2,725,814
Employee termination expenses		210,893		—		26,050
Write down of fixed assets for obsolescence		593,622		—		—
Litigation expenses		921,564		284,729		81,171
Accretion on collaboration, license and settlement agreements provision		63,400		308,938		693,047
Legal expenses and underwriters fees from financing activities		1,546,811		3,617,485		1,089,245
Other expenses		3,992,056		3,619,370		3,467,543
	$	14,655,957	$	14,081,153	$	10,013,732
Product development and clinical trials expenses
Depreciation		363,962		487,152		459,419
Share-based payments		798,811		1,764,557		1,252,218
Cash-based employee expenses		5,413,213		7,965,627		7,623,347
Other expenses		8,873,015		10,184,259		10,685,975
	$	15,449,001	$	20,401,595	$	20,020,959
TOTAL EXPENSES	$	33,101,250	$	36,679,551	$	31,680,676
Depreciation per Statements of Cash Flows	$	670,977	$	768,101	$	641,621
Share-based payments per Statements of Cash Flows	$	5,285,813	$	4,905,812	$	3,189,808
Cash-based employee expenses (see Note 20)	$	9,553,852	$	12,006,724	$	10,875,930